Loading cancer entity…
Loading cancer entity…
Clinical trials
673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (86)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01175356 | Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin | completed | Phase 1 | 99 | Children's Oncology GroupNETWORK | 1 | Jan 23, 2026 | clinicaltrials |
| NCT01231906 | Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma | completed | Phase 3 | 642 | Children's Oncology GroupNETWORK | 6 | Jan 23, 2026 |
| clinicaltrials |
| NCT07334301 | A Multi-Arm, Platform Trial For Relapsed Neuroblastoma(BEACON2) | recruiting | Phase 1 / Phase 2 | 160 | University of BirminghamOTHER | 5 | Jan 12, 2026 | clinicaltrials |
| NCT03057626 | Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma | active not recruiting | — | 376 | Children's Oncology GroupNETWORK | 4 | Jan 9, 2026 | clinicaltrials |
| NCT00085930 | Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients(NESTLES) | completed | Phase 1 | 19 | Baylor College of MedicineOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT01757626 | Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma | active not recruiting | Phase 1 / Phase 2 | 186 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05400603 | Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma(Aflac-NBL-2002) | recruiting | Phase 1 | 24 | Emory UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06803875 | Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma | recruiting | Phase 1 / Phase 2 | 42 | Roberto ChiarleOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT01850888 | MIBG for Refractory Neuroblastoma and Pheochromocytoma | completed | N/A | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03500991 | HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors | active not recruiting | Phase 1 | 10 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03638167 | EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors | completed | Phase 1 | 11 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT02307630 | PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study | active not recruiting | N/A | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06818916 | Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma | recruiting | N/A | 30 | Beijing Children's HospitalOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05770037 | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04081701 | 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.(DOMINO-START) | recruiting | Phase 4 | 200 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT00996710 | Genomic Structural Variation in Cancer Susceptibility | active not recruiting | — | 1,275 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT02162732 | Molecular-Guided Therapy for Childhood Cancer | completed | N/A | 186 | Giselle ShollerOTHER | 2 | Nov 3, 2025 | clinicaltrials |
| NCT07223606 | Fecal Microbiota Transplant for Neuroblastoma in a Single Patient | no longer available | — | — | ProgenaBiomeOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT04385277 | Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) | active not recruiting | Phase 2 | 41 | Children's Oncology GroupNETWORK | 4 | Oct 27, 2025 | clinicaltrials |
| NCT02605421 | Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma | recruiting | Phase 2 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT02508038 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT00588068 | Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome | recruiting | — | 2,070 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT05429502 | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | terminated | Phase 1 | 12 | Novartis PharmaceuticalsINDUSTRY | 4 | Oct 10, 2025 | clinicaltrials |
| NCT03033303 | A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma | completed | Phase 2 | 59 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT02245997 | Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma | completed | Early Phase 1 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT07195500 | Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma | recruiting | — | 30 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT03294954 | GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma(GINAKIT2) | recruiting | Phase 1 | 70 | Baylor College of MedicineOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04023331 | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma | terminated | Phase 1 / Phase 2 | 21 | Clarity Pharmaceuticals LtdINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT03107988 | NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) | completed | Phase 1 | 65 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 4 | Sep 15, 2025 | clinicaltrials |
| NCT06798532 | Interest of Preoperative Arteriography to Identify the Adamkiewicz Artery Before Surgery for Basi-thoracic Neuroblastic Tumors(AKA-NBL) | not yet recruiting | — | 150 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07167329 | Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial(BELIEVE-VHL) | recruiting | Phase 2 | 100 | José Claudio Casali da RochaOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07111117 | Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma.(NEUROBLASTOTEP) | not yet recruiting | Phase 2 | 30 | Institut CurieOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07141862 | Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method(PREFERPUBER) | recruiting | — | 89 | University Hospital, Clermont-FerrandOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT05135975 | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | recruiting | Phase 2 | 86 | Nationwide Children's HospitalOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05012098 | Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06852807 | 18F-mFBG PET Imaging in the Evaluation of Neuroblastoma | recruiting | — | 200 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT02650648 | Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | completed | Phase 1 | 85 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07067346 | Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma | recruiting | Early Phase 1 | 10 | Sichuan UniversityOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07090538 | GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma. | not yet recruiting | Early Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06872489 | Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors | available | — | — | Second Life TherapeuticsINDUSTRY | 0 | Jul 23, 2025 | clinicaltrials |
| NCT05192980 | SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours(BIOPORTAL) | recruiting | N/A | 600 | Institut CurieOTHER | 4 | Jul 22, 2025 | clinicaltrials |
| NCT07064746 | Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma(MIBG & SSTR NB) | recruiting | — | 150 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Jul 21, 2025 | clinicaltrials |
| NCT07072143 | An International Study on Pediatric Patients With Rare Tumors.(PARTNER) | recruiting | — | 6,250 | Azienda Ospedaliera di PadovaOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | terminated | Phase 1 | 40 | Actuate Therapeutics Inc.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06485947 | Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma(DBPilot) | recruiting | Phase 1 | 38 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT00703222 | A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells(CHESAT) | completed | Phase 1 / Phase 2 | 7 | Baylor College of MedicineOTHER | 1 | Jul 4, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jan 23, 2026source: clinicaltrials